AMP Launches its CBD Brand, CANAVEX® at YES!CON
ERFURT, Germany and BERLIN – AMP Alternative Medical Products Inc. (Frankfurt: C4TA), ISIN: CA0318961038 (CSE: XCX), a pharmaceutical supplier of cosmetic CBD cannabis products to German pharmacies, announced the launch of its newly developed CBD brand, CANAVEX®, sold in German pharmacies without a doctor’s prescription, which are distributed thru AMP Alternative Medical Products GmbH.
CBD is the most common non-psychoactive component found in the cannabis plant, and it has been found to offer a wide range of benefits.
AMP created CANAVEX® for cosmetic use and sold exclusively by pharmacists without a doctor’s prescription. CANAVEX® formulation includes high quality CBD, which is sourced from Germany and EU-GMP compliant, organic hemp seed oil and vitamin E.
CANAVEX®’s initial products are Basic CBD 5, which contains 500mg or 5% CBD and Basic CBD 10, which contains 1,000 mg or 10% CBD and are available in 10 ml sizes.
AMP will formally launch the CANAVEX® brand at the 2nd annual YES!CON cancer convention to be held in Berlin on September 18th and 19th, where Ursula von der Leyen, President of the European Commission, and Jens Spahn, Federal Minister of Health (Germany), and 120 other speakers will exchange inspiration, information, ideas, empowerment and lifestyle around the topic of cancer.
YES!CON is organized by “YesWeCan! cer,” Germany’s largest digital cancer patient platform for patient support and developer of the YES!APP, which helps cancer patients exchange information.
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accept responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements that are based on the Company’s expectations, estimates and projections regarding its business and the economic environment in which it operates, including with respect to its business plans and milestones and the timing thereof. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements do not guarantee future performance and involve risks and uncertainties that are difficult to control or predict. Therefore, actual outcomes and results may differ materially from those expressed in these forward-looking statements and readers should not place undue reliance on such statements. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances unless otherwise required to do so by law.
(This information is primarily sourced from AMP Alternative Medical Products Inc. Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).
Reunion Neuroscience to be Acquired by MPM BioImpact in $13.1 Million All-Cash Deal
LOS ANGELES-- Reunion Neuroscience Inc. a clinical-stage biopharmaceutical company specializing in innovative therapies for underserved mental health conditions, has announced a definitive arrangement agreement with MPM BioImpact, a leading biotechnology investment firm. Under the agreement, ...
California’s Regulated Cannabis Market Sees Decline in Sales and Tax Revenue in Q1 2023
LOS ANGELES-- California's hopes of increased consumer participation in the regulated cannabis market did not translate into a boost in licensed retail sales or state tax revenue during the first quarter of 2023. According to ...
C21 Investments Repays $30 Million Debt to CEO Sonny Newman
LOS ANGELES-- C21 Investments Inc., a vertically integrated cannabis company, announced today the successful completion of the full repayment of its $30 million senior secured note owed to Sonny Newman, the Company's President and Chief ...